Enzymatic versus plasmid DNA for rAAV production: early development insights that lead to manufacturing success

Wednesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET

Sponsor

Enzymatic versus plasmid DNA for rAAV production: early development insights that lead to manufacturing success

Live30 webinars pack the latest innovations and applications into a data-rich 30-minute session.

This webinar presents comparative data on the use of enzymatic DNA (neDNA™) and plasmid DNA (pDNA) in recombinant AAV (rAAV) production across multiple serotypes. Attendees will see how differences in DNA source affect key manufacturing parameters such as residual DNA content, and overall product quality, providing critical information to guide material selection.

The session will also explore optimization studies designed to refine rAAV manufacturing workflows. By understanding how early construct optimization and platform evaluation influence downstream performance, developers can accelerate timelines and enhance consistency while maintaining safety and regulatory readiness.

Participants will learn strategies to evaluate and select the most suitable DNA starting material based on project goals, cost, and scale requirements, with practical guidance for integrating these insights into current manufacturing processes.

Why attend:

Review comparative data showing how neDNA and pDNA-derived rAAV vectors differ in yield, purity, and residual DNA profiles
Learn how early optimization activities can shorten development timelines and improve product quality
Understand how DNA source selection impacts process efficiency, scalability, and compliance

Leticia Agundez, PhD

R&D Services Senior Manager at TAAV

Leticia Agundez graduated with a bachelor’s degree in biochemistry from the University of the Basque Country (Spain) and obtained a PhD in molecular microbiology from the University of Cantabria (Spain). During her postdoctoral research work at King’s College London (KCL), she focused her studies on AAV biology. Later, at University College London (UCL), she worked on gene editing and gene and cell therapies for the treatment of retinal disorders. With more than 15 years of experience in basic and translational research, she is an expert in the fields of molecular biology, AAV and gene therapies. Since August 2019, Leticia has led the R&D Services department at TAAV.

Elisa Da Silva Ferrada, PhD

Research Vector Core Manager at Viralgen Vector Core

Elisa da Silva Ferrada has both a bachelors and a master’s degree in Genetics and Biotechnology from UTAD (Vila Real, Portugal) and a PhD in Biomolecular Medicine from UPV (Bilbao, Spain) with more than 15 years of experience in molecular and cellular biology. The last 7 years of her professional career have been dedicated to AAV production in various roles at Viralgen.

in 32

Days

You have registered for this webinar